Breast Tumor Specific Peptides: Development of Breast Carcinoma Diagnostic and Therapeutic Agents
Abstract
The goal of the proposed research is to develop breast tumor-avid peptides as potential in vivo imaging or therapeutic agents. Peptides that specifically bound two breast tumor antigens, the Thomsen-Friedenreich (T) antigen and the erb-B2 receptor, were identified from random peptide bacteriophage display libraries. The T 99m antigen-avid peptides were labeled with Tc and shown to be radiochemically stable and bind cultured human breast tumor cells in vitro. In vivo biodistribution studies performed in normal mice showed that the peptides were stable in vivo and exhibited whole body clearance primarily through the GI tract Tumor targeting studies with the Tc-labeled peptides will begin shortly in breast tumor bearing mice. In addition, bacteriophage display libraries, displaying random peptides of various lengths, were screened with recombinant erbB-2 extracellular domain protein. Sequencing of erbB-2 binding clones has yielded the first consensus peptide. More clones, will be sequenced and analyzed to identify additional erbB-2 binders. The erbB-2 binding peptides will be chemically synthesized, radiolabeled, and examined for their abilities to bind breast tumor cells in vitro and in vivo.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 1998
- Accession Number
- ADB249671
Entities
People
- Thomas C. Quinn
Organizations
- University of Missouri